CA2648407A1 - Compositions and methods for treating polycystic kidney disease - Google Patents
Compositions and methods for treating polycystic kidney disease Download PDFInfo
- Publication number
- CA2648407A1 CA2648407A1 CA002648407A CA2648407A CA2648407A1 CA 2648407 A1 CA2648407 A1 CA 2648407A1 CA 002648407 A CA002648407 A CA 002648407A CA 2648407 A CA2648407 A CA 2648407A CA 2648407 A1 CA2648407 A1 CA 2648407A1
- Authority
- CA
- Canada
- Prior art keywords
- tnf
- alpha
- antibody
- cell
- fip2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 208000030761 polycystic kidney disease Diseases 0.000 title abstract description 11
- 230000037416 cystogenesis Effects 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 111
- 102100031822 Optineurin Human genes 0.000 claims description 82
- 101000992283 Homo sapiens Optineurin Proteins 0.000 claims description 80
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108010004408 TRPP Cation Channels Proteins 0.000 claims description 46
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 40
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 230000011664 signaling Effects 0.000 claims description 26
- 101150090168 rab8A gene Proteins 0.000 claims description 24
- 108020003175 receptors Proteins 0.000 claims description 24
- 230000003993 interaction Effects 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 102100032596 Fibrocystin Human genes 0.000 claims description 11
- 101710182545 Fibrocystin Proteins 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 210000003292 kidney cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000009460 calcium influx Effects 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- CAWYWWPWSAMGBV-UHFFFAOYSA-N 3-[(4-methylsulfonylphenyl)methylidene]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)=CC1=CC=C(S(C)(=O)=O)C=C1 CAWYWWPWSAMGBV-UHFFFAOYSA-N 0.000 claims description 3
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims description 3
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims description 3
- 208000035180 MODY Diseases 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 3
- 229950010444 onercept Drugs 0.000 claims description 3
- 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 claims description 3
- 229960003676 tenidap Drugs 0.000 claims description 3
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims 1
- -1 wherein the antibody Substances 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 92
- 239000011575 calcium Substances 0.000 abstract description 8
- 229910052791 calcium Inorganic materials 0.000 abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 230000004075 alteration Effects 0.000 abstract description 2
- 102100036142 Polycystin-2 Human genes 0.000 description 98
- 101710146368 Polycystin-2 Proteins 0.000 description 91
- 102100040247 Tumor necrosis factor Human genes 0.000 description 89
- 208000031513 cyst Diseases 0.000 description 41
- 102100036143 Polycystin-1 Human genes 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 36
- 101710146367 Polycystin-1 Proteins 0.000 description 32
- 210000003734 kidney Anatomy 0.000 description 30
- 206010011732 Cyst Diseases 0.000 description 27
- 210000004081 cilia Anatomy 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000004807 localization Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000012010 growth Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 206010061481 Renal injury Diseases 0.000 description 10
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 201000008519 polycystic kidney disease 1 Diseases 0.000 description 9
- 230000001973 epigenetic effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 7
- 101001026882 Homo sapiens Serine/threonine-protein kinase D2 Proteins 0.000 description 7
- 210000002726 cyst fluid Anatomy 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000003125 immunofluorescent labeling Methods 0.000 description 6
- 102000043279 ADAM17 Human genes 0.000 description 5
- 108091007505 ADAM17 Proteins 0.000 description 5
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 101150056230 PKD1 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091005462 Cation channels Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016252 Huntingtin Human genes 0.000 description 2
- 108050004784 Huntingtin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101710131459 Optineurin Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000005309 stochastic process Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 238000003158 yeast two-hybrid assay Methods 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LXIKEPCNDFVJKC-UHFFFAOYSA-N 5-chloro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)C1=C(O)C1=CC=CS1 LXIKEPCNDFVJKC-UHFFFAOYSA-N 0.000 description 1
- DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 description 1
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100027823 Complexin-2 Human genes 0.000 description 1
- 101710137424 Complexin-2 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000797579 Homo sapiens E3 SUMO-protein ligase CBX4 Proteins 0.000 description 1
- 101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000219822 Macrotyloma axillare Species 0.000 description 1
- 235000001504 Macrotyloma uniflorum var. uniflorum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000545 Proprotein Convertase 2 Proteins 0.000 description 1
- 102000004088 Proprotein Convertase 2 Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 102000011070 Rab3 Human genes 0.000 description 1
- 108050001276 Rab3 Proteins 0.000 description 1
- 102100025219 Ras-related protein Rab-6A Human genes 0.000 description 1
- 101710113746 Ras-related protein Rab-6A Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 102100031834 Unconventional myosin-VI Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940059756 arava Drugs 0.000 description 1
- WZSUOQDIYKMPMT-UHFFFAOYSA-N argon krypton Chemical compound [Ar].[Kr] WZSUOQDIYKMPMT-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001553 co-assembly Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000046764 human CBX4 Human genes 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 230000029225 intracellular protein transport Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000009200 mechanosensation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108010049787 myosin VI Proteins 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108700009994 polycystic kidney disease 1 Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed herein are methods and compositions for the treatment of polycystic kidney disease or other diseases that are associated with alteration, either directly or indirectly, by tumor necrosis factor-alpha (TNF-.alpha.) of receptor-calcium channel complexes or calcium regulation such that cyst formation is stimulated.
Description
COMPOSITIONS AND METHODS FOR TREATING POLYCYSTIC
KIDNEY DISEASE
FIELD OF INVENTION
[0001] The present invention generally relates to methods and compositions for the treatment of autosomal dominant polycystic kidney disease (ADPKD) or other cyst-forming diseases. Specifically, the compositions and methods of the invention may be used to inhibit the formation of cysts associated with altered calcium regulation.
BACKGROUND OF INVENTION
KIDNEY DISEASE
FIELD OF INVENTION
[0001] The present invention generally relates to methods and compositions for the treatment of autosomal dominant polycystic kidney disease (ADPKD) or other cyst-forming diseases. Specifically, the compositions and methods of the invention may be used to inhibit the formation of cysts associated with altered calcium regulation.
BACKGROUND OF INVENTION
[0002] Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disorder characterized by cystic dilation of the kidney tubules. As the disease advances, cysts enlarge and eventually become isolated from their nephrons.
The resultant decrease in kidney function often necessitates hemodialysis or organ transplantation. The majority of ADPKD cases (85-90%) are caused by mutations within the PKD1 gene, which encodes a 460 kDa G protein-coupled receptor known as polycystin-1 (PC1) 1 '2.
Mutations in a second gene, PKD2, abrogate the function of the Ca2+-permeable cation channel protein, polycystin-2 (PC2) and account for 10-15% of all ADPKD cases 8'9'19'20 PC1 and PC2 form a complex through interaction of their cytoplasmic domain and reside, among other locations, the primary cilia at the apical surface of kidney epithelia. The primary cilium is an organelle that extends from the basal body and comprises organized arrays of microtubules and their associated proteins. Recent studies have implicated the primary cilia in a variety of physiological functions and human diseases, such as PKD. It is hypothesized that defects in cilia and polycycstin-mediated calcium signaling in response to fluid flow result in altered epithelial cell polarity, cell-cell contact and cell cycle control, leading to disruption of epithelial integrity and cystogenesis.
The resultant decrease in kidney function often necessitates hemodialysis or organ transplantation. The majority of ADPKD cases (85-90%) are caused by mutations within the PKD1 gene, which encodes a 460 kDa G protein-coupled receptor known as polycystin-1 (PC1) 1 '2.
Mutations in a second gene, PKD2, abrogate the function of the Ca2+-permeable cation channel protein, polycystin-2 (PC2) and account for 10-15% of all ADPKD cases 8'9'19'20 PC1 and PC2 form a complex through interaction of their cytoplasmic domain and reside, among other locations, the primary cilia at the apical surface of kidney epithelia. The primary cilium is an organelle that extends from the basal body and comprises organized arrays of microtubules and their associated proteins. Recent studies have implicated the primary cilia in a variety of physiological functions and human diseases, such as PKD. It is hypothesized that defects in cilia and polycycstin-mediated calcium signaling in response to fluid flow result in altered epithelial cell polarity, cell-cell contact and cell cycle control, leading to disruption of epithelial integrity and cystogenesis.
[0003] A particularly important question regarding the development of ADPKD
is how recessive loss of function mutations in PKD1 and PKD2 could cause cyst growth in both human and mice heterozygous for these mutations. Analysis of somatic mutations in isolated human cysts led to the hypothesis that cystogenesis in ADPKD results from clonal expansion of epithelial cells harboring "second hit" mutations affecting the functional copy of the polycystin gene, including mostly somatic loss of heterozygosity and in some cases point mutations that may alter gene expression or function. However, for this hypothesis to be the sole explanation for the autosomal dominant nature of the disease, one must assume that the PKD1 locus is exceptionally mutable, given the estimated 1 in 1000 frequency of ADPKD in the human population and 1 in 5 frequency of cyst development in PKD2-/+ mice. Other studies indicated that polycystin is expressed in most cyst lining cells and argued that somatic mutations may not be required for at least the adult form of ADPKD. A main caveat of the "two hit" hypothesis is the difficulty to directly demonstrate the causal relationship between somatic mutations and the disease phenotype, and it has been pointed out that the high frequency of mutations observed in cyst lining cells may be due to loss of proper growth control, similar to the high-level genetic instablility observed in cancer cells (Harris PC and Watson ML). Alternative to evoking genetic changes, it is possible that some epigenetic factors, probably those embedded in the cellular networks involving polycystins, is the culprit in the phenotypic expression of ADPKD. In short, the cause(s) of ADPKD are not currently fully understood, and as a consequence, devising treatment for the disease has not been fully successful. No cures are currently known.
is how recessive loss of function mutations in PKD1 and PKD2 could cause cyst growth in both human and mice heterozygous for these mutations. Analysis of somatic mutations in isolated human cysts led to the hypothesis that cystogenesis in ADPKD results from clonal expansion of epithelial cells harboring "second hit" mutations affecting the functional copy of the polycystin gene, including mostly somatic loss of heterozygosity and in some cases point mutations that may alter gene expression or function. However, for this hypothesis to be the sole explanation for the autosomal dominant nature of the disease, one must assume that the PKD1 locus is exceptionally mutable, given the estimated 1 in 1000 frequency of ADPKD in the human population and 1 in 5 frequency of cyst development in PKD2-/+ mice. Other studies indicated that polycystin is expressed in most cyst lining cells and argued that somatic mutations may not be required for at least the adult form of ADPKD. A main caveat of the "two hit" hypothesis is the difficulty to directly demonstrate the causal relationship between somatic mutations and the disease phenotype, and it has been pointed out that the high frequency of mutations observed in cyst lining cells may be due to loss of proper growth control, similar to the high-level genetic instablility observed in cancer cells (Harris PC and Watson ML). Alternative to evoking genetic changes, it is possible that some epigenetic factors, probably those embedded in the cellular networks involving polycystins, is the culprit in the phenotypic expression of ADPKD. In short, the cause(s) of ADPKD are not currently fully understood, and as a consequence, devising treatment for the disease has not been fully successful. No cures are currently known.
SUMMARY OF INVENTION
[0004] Provided herein is a method of inhibiting cyst formation, which may be by inhibiting TNF-a signaling. The TNF-a signaling may be selected from the group consisting of:
TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2, and TNF-a receptor-associated proteins.
Inhibiting TNF-a signaling may maintain polycystin function in a cell, which may be a pancreatic cell, kidney cell, or liver cell. TNF-a signaling may be inhibited in vitro or in vivo.
Maintaining polycystin function may inhibit cystogenesis and may also localize PC2 to the plasma membrane.
[0004] Provided herein is a method of inhibiting cyst formation, which may be by inhibiting TNF-a signaling. The TNF-a signaling may be selected from the group consisting of:
TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2, and TNF-a receptor-associated proteins.
Inhibiting TNF-a signaling may maintain polycystin function in a cell, which may be a pancreatic cell, kidney cell, or liver cell. TNF-a signaling may be inhibited in vitro or in vivo.
Maintaining polycystin function may inhibit cystogenesis and may also localize PC2 to the plasma membrane.
[0005] Also provided herein is a method of inhibiting the disruption of calcium influx into a cell, which may be by inhibiting TNF-a signaling and maintaining polycystin function in a cell. FIP2 interaction with PC2 may also be inhibited.
Inhibiting FIP2 interaction with PC2 may localize PC2 to the plasma membrane of a cell.
Inhibiting FIP2 interaction with PC2 may localize PC2 to the plasma membrane of a cell.
[0006] Further provided herein is a method of treating a haploinsufficiency-associated disease, which may be by inhibiting TNF-a signaling and maintaining polycystin function in a cell. The haploinsufficiency-associated disease may comprise autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, neurofibromatosis, neuroblastoma, or MODY diabetes. TNF-a signaling may be inhibited by an antibody to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2, or a TNF-a receptor-associated protein. TNF-a may also be inhibited by etanercept, infliximab, D2E7, CDP 571, CDP 870, onercept, OR1384, tenidap, rapamycin, or leflunomide.
[0007] Also provided herein is a composition, which may be an antibody or an antigen-binding fragment thereof. The antibody may be a monoclonal, IgG, or IgM antibody.
The antibody may also be a dimmer, trimer, or multimer. The antibody may be human, humanized, or part-human. The antibody may also be chimeric or recombinant.
The antibody may also be operatively attached to at least a first therapeutic or diagnostic agent. The antibody may also be operatively attached to at least a first and a second therapeutic agent. The antigen-binding fragment may be a scFv, Fv, Fab', Fab, diabody or F(ab')2 fragment.
The antibody or antigen-binding fragment thereof may bind substantially to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2, or a TNF-a receptor-associated protein. The binding may maintain polycystin function and inhibit cystogenesis.
The antibody may also be a dimmer, trimer, or multimer. The antibody may be human, humanized, or part-human. The antibody may also be chimeric or recombinant.
The antibody may also be operatively attached to at least a first therapeutic or diagnostic agent. The antibody may also be operatively attached to at least a first and a second therapeutic agent. The antigen-binding fragment may be a scFv, Fv, Fab', Fab, diabody or F(ab')2 fragment.
The antibody or antigen-binding fragment thereof may bind substantially to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2, or a TNF-a receptor-associated protein. The binding may maintain polycystin function and inhibit cystogenesis.
[0008] Further provided herein is a pharmaceutical composition, which may comprise a biologically effective amount of at least a first immunoconjugate.
The immunoconjugate may comprise an antibody or antigen-binding fragment thereof.
The antibody or antigen-binding fragment thereof may bind substantially to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2 or a TNF-a receptor-associated protein. The binding may inhibit cystogenesis and maintain polycystin function in a cell.
The immunoconjugate may comprise an antibody or antigen-binding fragment thereof.
The antibody or antigen-binding fragment thereof may bind substantially to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2 or a TNF-a receptor-associated protein. The binding may inhibit cystogenesis and maintain polycystin function in a cell.
[0009] Also provided herein is a compound, which may comprise an antibody or an antigen-binding portion thereof. The antibody or antigen-binding portion thereof may bind substantially to TNF-a, Rab8, TNF-a receptor, fibrocystin, FIP2 or a TNF-a receptor-associated protein. The antibody or antigen-binding portion thereof may be attached to a therapeutic agent.
The therapeutic agent may inhibit TNF-a signaling and may also maintain polycystin function in a cell.
BRIEF DESCRIPTION OF DRAWINGS
The therapeutic agent may inhibit TNF-a signaling and may also maintain polycystin function in a cell.
BRIEF DESCRIPTION OF DRAWINGS
[00010] This application contains at least one photograph executed in color.
Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee. The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee. The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[00011] FIG. lA-E. PC2 interaction with FIP2 in yeast and mammalian cells is shown. A, Deletion construct Ga14-AD-FIP2, shown schematically, was used to determine the interaction domains in FIP2 and PC2 with yeast two-hybrid assays. The strengths of interactions are indicated as either positive interaction (+) or lacking interaction (-);
and grey boxes represent coiled-coil regions. B, Deletion construct Ga14-BD-PC2 was used to determine the interaction domains in FIP2 and PC2 with yeast two-hybrid assays. The strengths of interactions are indicated as either positive interaction (+) or lacking interaction (-); and grey boxes represent coiled-coil regions. C, PC2 co-immunoprecipitated with FIP2 from lysates of 293T cells co-transfected with Myc-tagged PC2 and T7- or Flag-tagged FIP2 with PC2 antibody (96525), or respective anti-tag antibodies. The PC2-FIP2 complex can be co-immunoprecipitated reciprocally. D, Western blot analyses, on the left-hand side, revealed an increase in the protein levels of FIP2 but not PC2 upon TNF-a stimulation. E, Endogenous PC2 co-immunoprecipitated with FIP2 with anti-PC2 or FIP2 antibody. TNF-a induction resulted in an increase in the amount of PC2 that was pulled down by FIP2.
and grey boxes represent coiled-coil regions. B, Deletion construct Ga14-BD-PC2 was used to determine the interaction domains in FIP2 and PC2 with yeast two-hybrid assays. The strengths of interactions are indicated as either positive interaction (+) or lacking interaction (-); and grey boxes represent coiled-coil regions. C, PC2 co-immunoprecipitated with FIP2 from lysates of 293T cells co-transfected with Myc-tagged PC2 and T7- or Flag-tagged FIP2 with PC2 antibody (96525), or respective anti-tag antibodies. The PC2-FIP2 complex can be co-immunoprecipitated reciprocally. D, Western blot analyses, on the left-hand side, revealed an increase in the protein levels of FIP2 but not PC2 upon TNF-a stimulation. E, Endogenous PC2 co-immunoprecipitated with FIP2 with anti-PC2 or FIP2 antibody. TNF-a induction resulted in an increase in the amount of PC2 that was pulled down by FIP2.
[00012] FIG. 2A-M. TNF-a signaling disrupts PC2 localization in IMCD cells.
A-D, Double immunofluorescence staining of endogenous PC2 (green) and acetylated tubulin (ac-tub, red) before (A, A') or after (B, B') treatment with TNF-a, observed with confocal microscopy. TNF-a stimulation results in the loss of PC2 localization to the plasma membrane and primary cilia and enrichment of PC2 within the perinuclear regions (B, B'), overlapping with a Golgi marker (C). A' AND B' show enlarged cilia images in the boxed regions in A and B, respectively. The loss of proper localization of PC2 was not due to cell death, as the TNF-a-treated cells showed normal morphology and were negative for TUNEL staining (D). E-K, Transfection of siRNA against FIP2 into IMCD cells inhibited FIP2 expression and prevented mislocalization of PC2, caused by TNF-ox. E, Transfected IMCD cells with 4 different siRNA
against FIP2 showed diminished FIP2 expression (siRNA#08 had the strongest effect). F,G, Western blot to determine the FIP2 levels in IMCD cells which were transfected with siRNA#05 (F) and siRNA#08 (G) and then treated with TNF-(x for 16 hours showed diminished FIP2 expression. H-K, Immunofluorescence staining of IMCD cells transfected with siRNA#05 (H,I) or siRNA#08 (J,K) against FIP2 before (H, J) or after (I, K) treatment with TNF-a showed that siRNA prevented the mislocalization of PC2 (green) (within the perinuclear regions). L,M, Immunofluorescence staining of PC2 (green) and transfected Flag-tagged FIP2 (red), showed a loss of PC2 localization to the plasma membrane in cells transfected with FIP2. L, Flag-FIP2-transfected cell, demonstrating colocalization of PC2 and FIP2 in the perinuclear region, and M, an untransfected cell with normal PC2 localization.
A-D, Double immunofluorescence staining of endogenous PC2 (green) and acetylated tubulin (ac-tub, red) before (A, A') or after (B, B') treatment with TNF-a, observed with confocal microscopy. TNF-a stimulation results in the loss of PC2 localization to the plasma membrane and primary cilia and enrichment of PC2 within the perinuclear regions (B, B'), overlapping with a Golgi marker (C). A' AND B' show enlarged cilia images in the boxed regions in A and B, respectively. The loss of proper localization of PC2 was not due to cell death, as the TNF-a-treated cells showed normal morphology and were negative for TUNEL staining (D). E-K, Transfection of siRNA against FIP2 into IMCD cells inhibited FIP2 expression and prevented mislocalization of PC2, caused by TNF-ox. E, Transfected IMCD cells with 4 different siRNA
against FIP2 showed diminished FIP2 expression (siRNA#08 had the strongest effect). F,G, Western blot to determine the FIP2 levels in IMCD cells which were transfected with siRNA#05 (F) and siRNA#08 (G) and then treated with TNF-(x for 16 hours showed diminished FIP2 expression. H-K, Immunofluorescence staining of IMCD cells transfected with siRNA#05 (H,I) or siRNA#08 (J,K) against FIP2 before (H, J) or after (I, K) treatment with TNF-a showed that siRNA prevented the mislocalization of PC2 (green) (within the perinuclear regions). L,M, Immunofluorescence staining of PC2 (green) and transfected Flag-tagged FIP2 (red), showed a loss of PC2 localization to the plasma membrane in cells transfected with FIP2. L, Flag-FIP2-transfected cell, demonstrating colocalization of PC2 and FIP2 in the perinuclear region, and M, an untransfected cell with normal PC2 localization.
[00013] FIG. 3. TNF-(x modulates PC2 complex formation with Rab8 and PC1.
A, Co-immunoprecipitation of PC2 and Rab8 in cells stimulated with TNF-(x for various lengths of time, showing that the interaction was induced by TNF-oX. B,C, Reciprocal co-immunoprecipitation of PC1 and PC2. After TNF-(x induction, PC1 failed to be co-immunoprecipitated by a PC2 antibody (B), and PC2 by a PC1 antibody (C), even though the same amounts of PC1 and PC2 were immunoprecipitated with their respective antibodies in all time points. D,E, Merged double immunofluorescence staining of endogenous PC1 (green) and acetylated tubulin (ac-tub, red) before (D) or after (E) treatment with TNF-a, observed with confocal microscopy. The images shown are 2D projections of all the confocal sections. D' and E' show enlarged cilia images in the boxed regions in d and e, respectively.
A, Co-immunoprecipitation of PC2 and Rab8 in cells stimulated with TNF-(x for various lengths of time, showing that the interaction was induced by TNF-oX. B,C, Reciprocal co-immunoprecipitation of PC1 and PC2. After TNF-(x induction, PC1 failed to be co-immunoprecipitated by a PC2 antibody (B), and PC2 by a PC1 antibody (C), even though the same amounts of PC1 and PC2 were immunoprecipitated with their respective antibodies in all time points. D,E, Merged double immunofluorescence staining of endogenous PC1 (green) and acetylated tubulin (ac-tub, red) before (D) or after (E) treatment with TNF-a, observed with confocal microscopy. The images shown are 2D projections of all the confocal sections. D' and E' show enlarged cilia images in the boxed regions in d and e, respectively.
[00014] FIG. 4. TNF-(x inhibits fluid flow-induced cytosolic Ca2+ mobilization in IMCD cells. A, Control IMCD cells without the addition of TNF-(x display their normal Ca2+-response to fluid flow stimulation. B, Treatment with TNF-a for 16 h blocks the response of IMCD cells to flow stimulation. C, TNF-(x does not inhibit the ATP-induced increase in cytosolic calcium in IMCD cells. When challenged with 1 M ATP, both control (no treatment) and TNF-oc-treated cells (treated for either 4 or 16 hours) show an increase in cytosolic calcium.
Fifty cells were randomly selected within a cell population, and changes in their cytosolic calcium levels were averaged and plotted in the graphs.
[0010] FIG. 5. Treatment of cultured kidneys from E15.5 embryos with TNF-oc for 5 days, in concentrations ranging from 3.125 ng/mL to 25 ng/mL, resulted in the formation of numerous cysts in wild-type kidneys and enhanced cyst formation in Pkdl+/- and Pkd2+/-kidneys. A, Treatment of wild type cultured kidneys with 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL, or 25 ng/mL of TNF-(x triggered cyst formation. Each vertical pair of kidneys represents left and right kidneys from the same embryo. B,C, Treatment with 25 ng/mL or 12.5 ng/mL
TNF-(x triggered cyst formation in wild-type littermates and their respective (b) Pkdl+/-littermates or (c) Pkd2+/- littermates. D, Enlarged images of the kidneys from the kidney organ cultures with or without TNF-(x addition. Cyst-lining cells resulting from TNF-(x treatment exhibited the expected flat morphology, as opposed to the cuboidal shape characteristic of normal renal tubule lining cells.
[0011] FIG. 6 Quantification of TNF-(x levels in ADPKD human cysts by ELISA indicated that the TNF-(x concentration in small cysts reached the ng/mL
range and that there was an inverse relationship between cyst size and TNF-o concentration.
A, The data represent 20 cysts from 10 ADPKD patients. The horizontal axis indicates cyst volumes; the left vertical axis indicates TNF-o concentration; and the right vertical axis indicates total TNF-o amount in each cyst. Levels of FIP2 increased in ADPKD cells. B, The amount of FIP2 protein as well as TNF-o receptor (TNFR) was compared between cultured normal human kidney cells (NHK) and ADPKD human cyst lining cells (PKD) and there was a 2.5-fold increase of FIP2 in the PKD cells as well as a 4-fold increase of TNFR. Consistent with this, levels of TNFR
exhibited an increase of 35% in TNF-a-treated IMCD cells and an increase of 3.5-fold in Pkdl -/-mutant mouse cells, as compared to wild-type cells. C, Immunoblot analysis of TNF-a receptor (TNFR) protein levels, comparing wild-type cells with or without TNF-a treatment and wild-type and Pkd1-/- cells.
[0012] FIG. 7. Double negative feedback loops constitute an epigenetic switch controlling cystogenesis in ADPKD. A, Schematic diagram depicting the network harboring two double negative feedback loops connecting TNF-o signaling and cystogenesis. +:
positive effects; -: negative effects. In red: stochastic factors that could trigger the feedback loops. B-D, Simulation of ADPKD disease progression using functional Petri nets. Cyst formation was allowed to occur only when polycystin level falls below 0.4 (1 being the maximum). Below this threshold, cyst formation is a stochastic process with a probability of occurring that increases linearly as Pc1Pc21eve1 decreases; hence, cyst formation is continuous if Pc1Pc21eve1 falls to zero. Cysts decay was set to occur at a constant rate. Renal injury was set to occur with a probability of approximately 1% every 4 years. In the wild type (B), expression of polycystin proteins is high enough to ensure that functional polycystin level remains well above the threshold. In individuals harboring heterozygous polycystin gene mutations (C), a stochastic dip in functional polycystin levels, due to transcriptional fluctuation, or a spike in TNF-a level due renal injury, triggered the positive feedback loop, causing permanent disease onset. If feedback was inhibited in the heterozygous case (D), cysts could appear transiently due to dips in polycystin level, but uncontrolled cyst formation never occurred.
DETAILED DESCRIPTION
[0013] In an attempt to identify the components of the signaling pathway involving polycystins, we performed a yeast two-hybrid screen of a human fetal kidney cDNA
library, using bait containing the entire C-terminal intracellular domain of human PC2. This screen identified FIP2, a coiled coil-containing, TNF-oc-induced protein, as a potential PC2 binding partner. To test the specificity of this interaction and to map the PC2 interacting domain within FIP2, we made a series of deletion constructs of FIP2 (FIG. 1A) and tested their interaction with PC2 in the yeast two-hybrid system. As shown in FIG. 1A, of the three coiled-coil domains within FIP2, only the constructs containing the 2nd coiled-coil domain interacted with the PC2 C-terminal domain as efficiently as the full-length FIP2.
Deletion constructs containing either the N-terminal domain or the C-terminal domain of FIP2 did not interact with PC2, further indicating that the PC2-binding domain is located within the second coiled-coil region of FIP2 (amino acid 143-260). Co-transformation of yeast with the full-length FIP2 and a series of PC2 C-terminal deletion constructs showed that the FIP2-binding domain is located around the coiled-coil domain of PC2 between amino acid 741-802 (FIG. 1B). To gain biochemical evidence that PC2 associates with FIP2 in mammalian cells, lysates prepared from IMCD cells co-transfected with full-length myc-tagged PC2 and flag-tagged or T7-tagged FIP2 were immunoprecipitated with anti-flag, anti-T7, anti-Myc or an anti-PC2 antibody (FIG. 1C).
We found that PC2 co-immunoprecipitated with FIP2 but not when the control anti-IgG antibody was used for immunoprecipitation.
[0014] TNF-(x is a pro-inflammatory cytokine with a number of important biologic functions 26-29 . TNF-(x mRNA and proteins are markedly increased after hypertensive stress 34 and renal injury 3s-3~ It has been reported that in the cystic kidneys of cpk/cpk mice TNF-(x level was increased progressively with age . TNF-oc was also found to be present in the cyst fluid in the ADPKD patients 38 . These facts, together with the finding that PC2 binds a TNF-a-induced protein, suggest that TNF-(x may influence the expression or function of PC2.
Since TNF-(x can induce the expression of a number of genes, such as FIP2 40 , we first tested whether it also alters the expression of PC2. Western blot analyses of FIP2 and PC2 expression after TNF-(x induction revealed that TNF-(x increased the expression of FIP2 by 3-4 fold, but not that of PC2 at any of the time points investigated (FIG. 1D).
Immunoprecipitation using anti-FIP2 or anti-PC2 antibody could co-precipitate endogenous PC2 or FIP2, respectively, in IMCD
cells induced with TNF-(x (FIG. 1E). The amount of PC2 in the FIP2 immunoprecipitate increased as FIP21eve1 rose during the TNF-(x treatment (FIG. 1E).
Fifty cells were randomly selected within a cell population, and changes in their cytosolic calcium levels were averaged and plotted in the graphs.
[0010] FIG. 5. Treatment of cultured kidneys from E15.5 embryos with TNF-oc for 5 days, in concentrations ranging from 3.125 ng/mL to 25 ng/mL, resulted in the formation of numerous cysts in wild-type kidneys and enhanced cyst formation in Pkdl+/- and Pkd2+/-kidneys. A, Treatment of wild type cultured kidneys with 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL, or 25 ng/mL of TNF-(x triggered cyst formation. Each vertical pair of kidneys represents left and right kidneys from the same embryo. B,C, Treatment with 25 ng/mL or 12.5 ng/mL
TNF-(x triggered cyst formation in wild-type littermates and their respective (b) Pkdl+/-littermates or (c) Pkd2+/- littermates. D, Enlarged images of the kidneys from the kidney organ cultures with or without TNF-(x addition. Cyst-lining cells resulting from TNF-(x treatment exhibited the expected flat morphology, as opposed to the cuboidal shape characteristic of normal renal tubule lining cells.
[0011] FIG. 6 Quantification of TNF-(x levels in ADPKD human cysts by ELISA indicated that the TNF-(x concentration in small cysts reached the ng/mL
range and that there was an inverse relationship between cyst size and TNF-o concentration.
A, The data represent 20 cysts from 10 ADPKD patients. The horizontal axis indicates cyst volumes; the left vertical axis indicates TNF-o concentration; and the right vertical axis indicates total TNF-o amount in each cyst. Levels of FIP2 increased in ADPKD cells. B, The amount of FIP2 protein as well as TNF-o receptor (TNFR) was compared between cultured normal human kidney cells (NHK) and ADPKD human cyst lining cells (PKD) and there was a 2.5-fold increase of FIP2 in the PKD cells as well as a 4-fold increase of TNFR. Consistent with this, levels of TNFR
exhibited an increase of 35% in TNF-a-treated IMCD cells and an increase of 3.5-fold in Pkdl -/-mutant mouse cells, as compared to wild-type cells. C, Immunoblot analysis of TNF-a receptor (TNFR) protein levels, comparing wild-type cells with or without TNF-a treatment and wild-type and Pkd1-/- cells.
[0012] FIG. 7. Double negative feedback loops constitute an epigenetic switch controlling cystogenesis in ADPKD. A, Schematic diagram depicting the network harboring two double negative feedback loops connecting TNF-o signaling and cystogenesis. +:
positive effects; -: negative effects. In red: stochastic factors that could trigger the feedback loops. B-D, Simulation of ADPKD disease progression using functional Petri nets. Cyst formation was allowed to occur only when polycystin level falls below 0.4 (1 being the maximum). Below this threshold, cyst formation is a stochastic process with a probability of occurring that increases linearly as Pc1Pc21eve1 decreases; hence, cyst formation is continuous if Pc1Pc21eve1 falls to zero. Cysts decay was set to occur at a constant rate. Renal injury was set to occur with a probability of approximately 1% every 4 years. In the wild type (B), expression of polycystin proteins is high enough to ensure that functional polycystin level remains well above the threshold. In individuals harboring heterozygous polycystin gene mutations (C), a stochastic dip in functional polycystin levels, due to transcriptional fluctuation, or a spike in TNF-a level due renal injury, triggered the positive feedback loop, causing permanent disease onset. If feedback was inhibited in the heterozygous case (D), cysts could appear transiently due to dips in polycystin level, but uncontrolled cyst formation never occurred.
DETAILED DESCRIPTION
[0013] In an attempt to identify the components of the signaling pathway involving polycystins, we performed a yeast two-hybrid screen of a human fetal kidney cDNA
library, using bait containing the entire C-terminal intracellular domain of human PC2. This screen identified FIP2, a coiled coil-containing, TNF-oc-induced protein, as a potential PC2 binding partner. To test the specificity of this interaction and to map the PC2 interacting domain within FIP2, we made a series of deletion constructs of FIP2 (FIG. 1A) and tested their interaction with PC2 in the yeast two-hybrid system. As shown in FIG. 1A, of the three coiled-coil domains within FIP2, only the constructs containing the 2nd coiled-coil domain interacted with the PC2 C-terminal domain as efficiently as the full-length FIP2.
Deletion constructs containing either the N-terminal domain or the C-terminal domain of FIP2 did not interact with PC2, further indicating that the PC2-binding domain is located within the second coiled-coil region of FIP2 (amino acid 143-260). Co-transformation of yeast with the full-length FIP2 and a series of PC2 C-terminal deletion constructs showed that the FIP2-binding domain is located around the coiled-coil domain of PC2 between amino acid 741-802 (FIG. 1B). To gain biochemical evidence that PC2 associates with FIP2 in mammalian cells, lysates prepared from IMCD cells co-transfected with full-length myc-tagged PC2 and flag-tagged or T7-tagged FIP2 were immunoprecipitated with anti-flag, anti-T7, anti-Myc or an anti-PC2 antibody (FIG. 1C).
We found that PC2 co-immunoprecipitated with FIP2 but not when the control anti-IgG antibody was used for immunoprecipitation.
[0014] TNF-(x is a pro-inflammatory cytokine with a number of important biologic functions 26-29 . TNF-(x mRNA and proteins are markedly increased after hypertensive stress 34 and renal injury 3s-3~ It has been reported that in the cystic kidneys of cpk/cpk mice TNF-(x level was increased progressively with age . TNF-oc was also found to be present in the cyst fluid in the ADPKD patients 38 . These facts, together with the finding that PC2 binds a TNF-a-induced protein, suggest that TNF-(x may influence the expression or function of PC2.
Since TNF-(x can induce the expression of a number of genes, such as FIP2 40 , we first tested whether it also alters the expression of PC2. Western blot analyses of FIP2 and PC2 expression after TNF-(x induction revealed that TNF-(x increased the expression of FIP2 by 3-4 fold, but not that of PC2 at any of the time points investigated (FIG. 1D).
Immunoprecipitation using anti-FIP2 or anti-PC2 antibody could co-precipitate endogenous PC2 or FIP2, respectively, in IMCD
cells induced with TNF-(x (FIG. 1E). The amount of PC2 in the FIP2 immunoprecipitate increased as FIP21eve1 rose during the TNF-(x treatment (FIG. 1E).
[0015] Since TNF-(x did not affect the level of PC2 expression, we tested whether localization of PC2 was altered in TNF-a-treated cells. Immunofluorescence staining using anti-PC2 antibody in the untreated IMCD cells showed that the endogenous PC2 localized to the plasma membrane, especially enriched in the primary cilia in IMCD cells (FIG.
2A,A'), as demonstrated in previous work 21. However, in cells treated with TNF-oc for 16 hours, we observed a striking difference in PC2 localization: PC2 no longer localized to the plasma membrane but was strongly enriched in perinuclear regions, overlapping with a Golgi marker (FIG. 2C), and the cilia were completely devoid of PC2 (FIG. 2B,B'). The loss of proper localization of PC2 was not due to cell death, as the TNF-a-treated cells showed normal morphology and were negative for TUNEL staining (FIG. 2D). To test if this observed effect was due to elevated FIP2 expression, we over-expressed Flag-tagged FIP2 in IMCD cells by transient transfection and we transfected IMCD cells with siRNA against FIP2.
2A,A'), as demonstrated in previous work 21. However, in cells treated with TNF-oc for 16 hours, we observed a striking difference in PC2 localization: PC2 no longer localized to the plasma membrane but was strongly enriched in perinuclear regions, overlapping with a Golgi marker (FIG. 2C), and the cilia were completely devoid of PC2 (FIG. 2B,B'). The loss of proper localization of PC2 was not due to cell death, as the TNF-a-treated cells showed normal morphology and were negative for TUNEL staining (FIG. 2D). To test if this observed effect was due to elevated FIP2 expression, we over-expressed Flag-tagged FIP2 in IMCD cells by transient transfection and we transfected IMCD cells with siRNA against FIP2.
[0016] IMCD cells were transiently transfected with full length FIP2. PC2 localization to the plasma membrane was diminished in the FIP2 transfected cells but not in the surrounding non-transfected cells, and PC2 colocalizes with FIP2 in perinuclear structures (FIG.
2L, M). FIP2 siRNA reduced FIP2 expression by 95% (FIG. 2E-G) and restored normal PC2 localization in TNF-a-treated cells (FIG. 2H-K). These results suggest that induction of FIP2 downstream of TNF-a signaling disrupts PC2 localization to its normal site of function.
2L, M). FIP2 siRNA reduced FIP2 expression by 95% (FIG. 2E-G) and restored normal PC2 localization in TNF-a-treated cells (FIG. 2H-K). These results suggest that induction of FIP2 downstream of TNF-a signaling disrupts PC2 localization to its normal site of function.
[0017] The lack of PC2 cilia localization and accumulation of PC2 in the perinuclear region in TNF-oc-treated cells raised the possibility that PC2 was prevented from effectively trafficking through the exocytic pathway or was mis-sorted. In support of this possibility, FIP2, also known as Optineurin, was previously found to be a binding partner for the GTP-bound form of Rab8, a GTPase localized in the recycling endosomes and important for basal-lateral protein targeting . FIP2 interacts with Rab8 through the N-terminal -200 amino acid and was shown to link the Huntingtin protein and myosin VI to Rab8 . To test if FIP2 plays a role in promoting complex formation between PC2 and Rab8, an antibody specific to Rab8 was used in immunoprecipitation experiments. Without TNF-a stimulation, PC2 did not co-immunoprecipiate with Rab8, even though Rab8 protein level was unaffected by TNF-oc treatment. In cells treated with TNF-a for 4 or 16 hours, PC2 was clearly present in Rab8 immunoprecipitate (FIG. 3A). This result suggests that TNF-a treatment induces the formation of a PC2-FIP2-Rab8 complex, which hijacks PC2 from the apical membrane and accumulates it in the perinuclear structures, likely to be the recycling endosomes where Rab8 was previously shown to reside . The Huntingtin protein, another binding partner for FIP2, was also shown to be sequestered, upon over-expression of FIP2, to perinuclear particulate structures that contained Rab8 in HT1080 cells.
[0018] The function of PC2 requires formation of a mechanosensitive receptor-channel complex with PC1, which transduces mechanical signals such as fluid flow sheer stress into a chemical signal important for epithelial tissue homeostasis is. The C-terminal cytoplasmic domain of PC2 that binds to PC1 overlaps with the domain that binds FIP2. In cells not treated with TNF-a, PC1 and PC2 can be co-immunoprecipiated with the antibody against either protein (FIG. 3B, C). After TNF-a induction, however, this interaction was no longer detectable, even though the expression levels of PC1 and PC2 remained the same as in the untreated cells.
Furthermore, immunofluorescence staining of PC1 with the antibody 96521 revealed that PC1 remained on the primary cilia after TNF-a treatment, although we noticed subtle but reproducible changes: whereas in the untreated cells PC1 localizes along the entire length of the cilia, in the TNF-a treated cells, PC1 was often absent at either end of the cilia (FIG.
3D,D',E,E'). The subtle alteration in PC1 localization could result from the absence of its normal binding partner, PC2, on cilia membrane.
Furthermore, immunofluorescence staining of PC1 with the antibody 96521 revealed that PC1 remained on the primary cilia after TNF-a treatment, although we noticed subtle but reproducible changes: whereas in the untreated cells PC1 localizes along the entire length of the cilia, in the TNF-a treated cells, PC1 was often absent at either end of the cilia (FIG.
3D,D',E,E'). The subtle alteration in PC1 localization could result from the absence of its normal binding partner, PC2, on cilia membrane.
[0019] It was recently shown that the co-distribution of PC1 and PC2 in the primary cilium mediates Ca2+ influx in response to physiological fluid flow over the apical surface. Because TNF-a stimulation disrupts the PC2-PC1 complex and PC2 localization to the cilia, TNF-oc should also abrogate fluid flow-induced Ca2+ influx. To test this prediction, we performed flow assay in IMCD cells after 16 hours TNF-a stimulation. We found that TNF-a stimulation completely abolished the flow-induced Ca2+ response, whereas a normal flow-induced Ca2+ response was seen in the control IMCD cells (FIG. 4A-B). This effect was specific, as TNF-a did not affect the Ca2+rise in response to ATP (FIG. 4C).
[0020] The above results suggest a pathway through which TNF-o could down-regulate polycystin function and thereby stimulate cyst growth. This pathway could be an important contributing factor in the onset of ADPKD. To test this hypothesis, a mouse embryonic kidney organ culture system was used to determine if TNF-a can induce cyst formation in kidneys from wild-type, PKD 1+/- and PKD2+/- mice. Previously, it was found that cAMP, an activator of in vitro cyst formation, induced cyst formation in cultured mouse E13.5 kidneys. The culture conditions were modified using E15.5-E17.5 kidneys such that no cyst formation was observed in the absence of TNF-a. However, treatment for five days with concentrations as low as 6.25 ng/ml TNF-a resulted in the formation of numerous cysts in wild-type kidneys (FIG. 5A), and enhanced cyst formation in Pkdl+/- and Pkd2+/-kidneys (FIG.
5B,C). Cyst-lining cells resulting from TNF-a treatment exhibited the expected flat morphology, as opposed to the cuboidal shape characteristic of normal renal tubule cells (FIG. 5D). These results provide direct evidence that TNF-a promotes kidney cyst formation.
5B,C). Cyst-lining cells resulting from TNF-a treatment exhibited the expected flat morphology, as opposed to the cuboidal shape characteristic of normal renal tubule cells (FIG. 5D). These results provide direct evidence that TNF-a promotes kidney cyst formation.
[0021] Furthermore, the presence of TNF-a in cyst fluids from ADPKD patients has been reported in a previous study, which measured 10-73 pg/ml TNF-a in cyst fluids from ADPKD patients. The effective concentrations that we have observed with kidney organ cultures were in the ng/ml range. We measured the concentration of TNF-a in cyst fluids obtained from 10 ADPKD patients by using ELISA. The TNF-a concentration in small cysts reached the ng/ml range, with the highest concentration reaching 3.8 ng/ml.
There was an inverse relationship between cyst size and TNF-a concentration (FIG. 6A), suggesting that TNF-a might be diluted in the lumens of large cysts. Importantly, the total amount of TNF-a appeared to increase with larger cyst size (FIG. 6A), suggesting that TNF-a might be continuously accumulated as cysts grow. To determine if FIP2 levels are increased in ADPKD
cells, the amount of FIP2 protein was compared between cultured normal human kidney cells (NHK) and ADPKD human cyst lining cells (PKD). As shown in FIG. 6B, top panel, there was a 2.5-fold increase of FIP2 in the PKD cells. The levels of TNF-a receptor (TNFR) also exhibited an increase (about 4-fold) in the cyst lining cells (PKD) (FIG. 6B, middle panel). Consistent with this, in comparing wild-type IMCD cells, with or without TNF-a treatment, or wild-type and pkdl -/- mutant kidney epithelial cell lines, TNFR levels were increased by 35% in TNF-a-treated IMCD cells and were increased 3.5-fold in Pkdl -/- mutant mouse cells, as compared to wild-type cells (FIG. 6C). This result indicates that exposure to TNF-a or loss of polycystin function could stimulate expression of TNFR, and this change could render the epithelia even more sensitive to TNF-a.
There was an inverse relationship between cyst size and TNF-a concentration (FIG. 6A), suggesting that TNF-a might be diluted in the lumens of large cysts. Importantly, the total amount of TNF-a appeared to increase with larger cyst size (FIG. 6A), suggesting that TNF-a might be continuously accumulated as cysts grow. To determine if FIP2 levels are increased in ADPKD
cells, the amount of FIP2 protein was compared between cultured normal human kidney cells (NHK) and ADPKD human cyst lining cells (PKD). As shown in FIG. 6B, top panel, there was a 2.5-fold increase of FIP2 in the PKD cells. The levels of TNF-a receptor (TNFR) also exhibited an increase (about 4-fold) in the cyst lining cells (PKD) (FIG. 6B, middle panel). Consistent with this, in comparing wild-type IMCD cells, with or without TNF-a treatment, or wild-type and pkdl -/- mutant kidney epithelial cell lines, TNFR levels were increased by 35% in TNF-a-treated IMCD cells and were increased 3.5-fold in Pkdl -/- mutant mouse cells, as compared to wild-type cells (FIG. 6C). This result indicates that exposure to TNF-a or loss of polycystin function could stimulate expression of TNFR, and this change could render the epithelia even more sensitive to TNF-a.
[0022] A network scheme emerging from above results consists of two nested double negative feedback loops connecting TNF-o signaling, polycystin function and cystogenesis (FIG. 7A). Double negative feedback loops are observed in many regulatory networks that give rise to bistable system behavior in such processes as cell cycle transition and cell fate determination . Positive feedback loops and double negative loops have the potential to turn transient and minute signals to stable end states. We hypothesize that such regulatory system could also function as an "epigenetic switch" controlling the stable transition from the healthy state to the disease state in response to spontaneous perturbation of the normal function.
In the case of ADPKD, it is conceivable that an acute increase in TNF-a level could result from hypertensive stress 34 and renal injury 35-37 and could activate the feedback loops and precipitate full-scale cystogenesis. There are indeed clinical observations linking hypertension and renal injury to the progression of PKD . Stochastic triggers of the epigenetic switch could also result from fluctuations in gene expression. There is increasing evidence that the initiation and termination of gene transcription are probabilistic, giving rise to high noise in gene expression. The degree of expression fluctuation is increased with reduced gene copy number.
In cells with only a single copy of functional PKD1 or 2 gene, where the steady-state level of gene expression is on average only 50% of the normal, the probability of the gene product level stochastically dipping below certain functional threshold would be much higher than in normal cells. Consequently, the high probability of triggering the epigenetic switch due to sub-threshold level of polycystin function would result in sudden transition to and perpetuation of a stable disease state. A similar mechanism has been proposed for at least another autosomal dominant disease - maturity-onset diabetes of the young.
In the case of ADPKD, it is conceivable that an acute increase in TNF-a level could result from hypertensive stress 34 and renal injury 35-37 and could activate the feedback loops and precipitate full-scale cystogenesis. There are indeed clinical observations linking hypertension and renal injury to the progression of PKD . Stochastic triggers of the epigenetic switch could also result from fluctuations in gene expression. There is increasing evidence that the initiation and termination of gene transcription are probabilistic, giving rise to high noise in gene expression. The degree of expression fluctuation is increased with reduced gene copy number.
In cells with only a single copy of functional PKD1 or 2 gene, where the steady-state level of gene expression is on average only 50% of the normal, the probability of the gene product level stochastically dipping below certain functional threshold would be much higher than in normal cells. Consequently, the high probability of triggering the epigenetic switch due to sub-threshold level of polycystin function would result in sudden transition to and perpetuation of a stable disease state. A similar mechanism has been proposed for at least another autosomal dominant disease - maturity-onset diabetes of the young.
[0023] We used a network model based on functional Petri nets [Doi, 2004;
Nagasaki, 2004] to simulate the induction of cystogenesis through the TNF-a-mediated epigenetic switch. Our modeling approach has adopted fuzzy logic methods from control systems engineering to modeling reaction kinetics [Kecman, 2001; Ross, 2004;
Tsoukalas, 1997]. Reactions are connected as in a Petri net and occur at every time step.
This model computes time courses for protein concentrations and gene expression levels from the network specification. A feature of this model is that reactions in the network may have a probability assigned, which allows stochastic processes to be represented (more details of the model can be found in Bosl, 2006. PC1 and PC2 are modeled as a functional unit, the level of which is affected by gene dosage of PKD1 and PKD2, as well as proper targeting of PC2 to the cilia, which is inhibited by FIP2. There are two sources of random fluctuations in the model:
stochastic gene expression and renal injury, which occurs infrequently but is sufficient to generate a spike in TNF-(x production. In the wild-type population, where two copies of the gene are present to direct each polycystin transcription, the fluctuation in functional PC1-PC21eve1 is less in magnitude than in the heterozygous situation and is always above the functional threshold required for preventing cyst initiation (FIG. 7B). However, in the heterozygous population, where the level of expression is in general sufficient to suppress cyst formation, random fluctuations may cause the feedback loops to be switched on and cyst growth continues unabated (FIG. 7C). Significantly, if the feedback loops are disabled, full-scale cystogenesis is prevented even with stochastic sub-threshold dips in polycystin level (FIG. 7D). It is important to state that the involvement of an epigenetic switch for the onset of ADPKD does not rule out disease induction due to loss of heterozygosity or other genetic modifications. In fact, genetic changes could be particularly important for the stabilization of the disease state and further enhance the rate of cyst growth and renal degeneration. Unraveling the epigenetic control pathways that potentially function as a "second hit" in ADPKD may provide hopeful targets, such as components of the TNF-(x signaling pathway, for therapeutic intervention of disease initiation and progression.
Nagasaki, 2004] to simulate the induction of cystogenesis through the TNF-a-mediated epigenetic switch. Our modeling approach has adopted fuzzy logic methods from control systems engineering to modeling reaction kinetics [Kecman, 2001; Ross, 2004;
Tsoukalas, 1997]. Reactions are connected as in a Petri net and occur at every time step.
This model computes time courses for protein concentrations and gene expression levels from the network specification. A feature of this model is that reactions in the network may have a probability assigned, which allows stochastic processes to be represented (more details of the model can be found in Bosl, 2006. PC1 and PC2 are modeled as a functional unit, the level of which is affected by gene dosage of PKD1 and PKD2, as well as proper targeting of PC2 to the cilia, which is inhibited by FIP2. There are two sources of random fluctuations in the model:
stochastic gene expression and renal injury, which occurs infrequently but is sufficient to generate a spike in TNF-(x production. In the wild-type population, where two copies of the gene are present to direct each polycystin transcription, the fluctuation in functional PC1-PC21eve1 is less in magnitude than in the heterozygous situation and is always above the functional threshold required for preventing cyst initiation (FIG. 7B). However, in the heterozygous population, where the level of expression is in general sufficient to suppress cyst formation, random fluctuations may cause the feedback loops to be switched on and cyst growth continues unabated (FIG. 7C). Significantly, if the feedback loops are disabled, full-scale cystogenesis is prevented even with stochastic sub-threshold dips in polycystin level (FIG. 7D). It is important to state that the involvement of an epigenetic switch for the onset of ADPKD does not rule out disease induction due to loss of heterozygosity or other genetic modifications. In fact, genetic changes could be particularly important for the stabilization of the disease state and further enhance the rate of cyst growth and renal degeneration. Unraveling the epigenetic control pathways that potentially function as a "second hit" in ADPKD may provide hopeful targets, such as components of the TNF-(x signaling pathway, for therapeutic intervention of disease initiation and progression.
[0024] In particular, inhibitors and antagonists of TNF-(x may be used to prevent or treat ADPKD. Inhibitors and antagonists of TNF-(x reduce or inhibit the action of TNF-ox.
These agents include fusion proteins, such as etanercept (Enbrel , Amgen and Wyeth);
monoclonal antibodies, such as infliximab (Remicade , Centocor), D2E7 (Humira , Abbott), and CDP 571 (Celltech); binding proteins, such as onercept (Serono); and antibody fragments, such as CDP 870 (Celltech and Pfizer). Other TNF-alpha antagonists and inhibitors include OR1384, tenidap (5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-l-carboxamide), rapamycin (sirolimus or Rapamune ), and leflunomide (Arava ).
These agents include fusion proteins, such as etanercept (Enbrel , Amgen and Wyeth);
monoclonal antibodies, such as infliximab (Remicade , Centocor), D2E7 (Humira , Abbott), and CDP 571 (Celltech); binding proteins, such as onercept (Serono); and antibody fragments, such as CDP 870 (Celltech and Pfizer). Other TNF-alpha antagonists and inhibitors include OR1384, tenidap (5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-l-carboxamide), rapamycin (sirolimus or Rapamune ), and leflunomide (Arava ).
[0025] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention.
More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
EXAMPLES
More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
EXAMPLES
[0026] Example 1. Cell culture [0027] IMCD (ATCC catalog no. CRL-2123) cells were cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% (v/v) fetal bovine serum (Invitrogen). The final concentration for TNF-a induction is 200 ng/ml for all the experiments. .
Mouse embryonic kidney (MEK) cells isolated from E15.5 wild-type and Pkdl mutant mice (Pkdl-/-) were cultured at 33 C as described previously (1). Cells were cultured to 30%-50%
confluence and transiently transfected with Fugene 6 transfection reagent (Roche, Indianapolis, IN) following the manufacturer's protocol. Cells were harvested for further analysis 48 hours after transfection.
Mouse embryonic kidney (MEK) cells isolated from E15.5 wild-type and Pkdl mutant mice (Pkdl-/-) were cultured at 33 C as described previously (1). Cells were cultured to 30%-50%
confluence and transiently transfected with Fugene 6 transfection reagent (Roche, Indianapolis, IN) following the manufacturer's protocol. Cells were harvested for further analysis 48 hours after transfection.
[0028] Example 2. Embryonic Kidney Organ Culture [0029] Embryonic kidneys were dissected in PBS (with calcium and magnesium) plus penicillin-streptomycin-glutamine (GiBCO, Grand Island, NY) from embryos of wild type CD1 mice at E15.5, E16.5 or E17.5 and of C57BL/6 Pkdl+/- or C57BL/6 Pkd2+/-mice or their wild type counterparts at E15.5. The dissected kidneys were cultured at 37 C
in DMEM/F12 containing 2 mM L-glutamine, 10 mM Hepes, 5 g/ml insulin, 5 g/ml transferrin, 2.8 mM
selenium, 25 ng/ml prostaglandin El, 32 pg/ml T3 and 250 U/ml penicillin-streptomycin. The kidneys were cultured with or without TNF-a at different concentrations for 48 hours and then 50 M 8-bromo-cyclic AMP (Sigma, St. Louis, MO) was added for 5 days. The cultured kidneys were then fixed with 4% paraformaldehyde (PFA) in PBS for 6 hours. Washed with PBS twice for 5 minutes each and transferred to 70% EtOH for short-term storage at room temperature or for more extended storage at 4 C. The fixed kidney samples were subsequently processed for Hematoxylin and Eosin staining following common histology protocol.
in DMEM/F12 containing 2 mM L-glutamine, 10 mM Hepes, 5 g/ml insulin, 5 g/ml transferrin, 2.8 mM
selenium, 25 ng/ml prostaglandin El, 32 pg/ml T3 and 250 U/ml penicillin-streptomycin. The kidneys were cultured with or without TNF-a at different concentrations for 48 hours and then 50 M 8-bromo-cyclic AMP (Sigma, St. Louis, MO) was added for 5 days. The cultured kidneys were then fixed with 4% paraformaldehyde (PFA) in PBS for 6 hours. Washed with PBS twice for 5 minutes each and transferred to 70% EtOH for short-term storage at room temperature or for more extended storage at 4 C. The fixed kidney samples were subsequently processed for Hematoxylin and Eosin staining following common histology protocol.
[0030] Example 3. TUNEL Assay [0031] Cells treated with or without TNF-a were fixed with 4% PFA. TUNEL
assay was performed using a fluorescent apoptosis-detection system (R&D
systems, Minneapolis, MN). Fixed cells were treated with TACS-nuclease for the positive control.
assay was performed using a fluorescent apoptosis-detection system (R&D
systems, Minneapolis, MN). Fixed cells were treated with TACS-nuclease for the positive control.
[0032] Example 4. Immunoprecipitation and Western Blot Analysis [0033] Immunoprecipitation and Western blotting were performed on whole-cell lysates as previously described (REFS). The antibodies used for Western blotting included rabbit polyclonal anti-FIP2 (2), rabbit anti-PC2 polyclonal antibody 96525 (1), rabbit anti-PC1 polyclonal antibody 96521, rabbit anti-Rab8 polyclonal antibody and rabbit anti-TNFR-I
polyclonal antibody. Secondary antibodies used include: goat-anti-rabbit IgG-fluorescein isothiocyanate (FITC Molecular Probes, Eugene, OR), goat-anti-mouse IgG-Texas Red, (1:500 dilution; Molecular Probes). For western blotting, goat-anti-rabbit Ig-horseradish peroxidase (HRP or goat-anti-mouse IgG-HRP, 1:10,000 dilution; Amersham Pharmacia Biotech) were used as secondary antibodies.
polyclonal antibody. Secondary antibodies used include: goat-anti-rabbit IgG-fluorescein isothiocyanate (FITC Molecular Probes, Eugene, OR), goat-anti-mouse IgG-Texas Red, (1:500 dilution; Molecular Probes). For western blotting, goat-anti-rabbit Ig-horseradish peroxidase (HRP or goat-anti-mouse IgG-HRP, 1:10,000 dilution; Amersham Pharmacia Biotech) were used as secondary antibodies.
[0034] Example 5. RNAi to Inhibit FIP2 Expression [0035] The oligo sequences used for FIP2 RNAi (Dharmacon, Chicago, IL) are listed below: #05 Sense sequence: 5'-GCUAUGAAAGGGCGAUUUGUU (SEQ ID NO: 1); #05 Antisense sequence: 5'-PCAAAUCGCCCUUUCAUAGCUU (SEQ ID NO:2); #06 Sense sequence: 5'-UGAGCUGCCUGACUGAGAAUU (SEQ ID NO:3); #06 Antisense sequence: 5'-PUUCUCAGUCAGGCAGCUCAUU (SEQ ID NO:4); #07 Sense sequence: 5'-GAAAUGCAGUGCCGACACGUU (SEQ ID NO:5); #07 Antisense sequence: 5'-PCGUGUCGGCACUGCAUUUCUU (SEQ ID NO:6); #08 Sense sequence: 5'-CCAUGAAGCUAAAUAAUCAUU (SEQ ID NO:7); #08 Antisense sequence: 5'-PUGAUUAUUUAGCUUCAUGGUU (SEQ ID NO:8).
[0036] The transfection was performed using the DharmaFECT siRNA
transfection reagent (Dharmacon, Chicago, IL).
transfection reagent (Dharmacon, Chicago, IL).
[0037] Example 6. Immunofluorescence Microscopy [0038] Immunofluorescence was carried out as previously described (1). Primary antibodies were used at the following dilutions: FIP2 (1:100), PC1 (1:500), PC2 (1:500), and flag (1:500). Secondary antibodies used included goat-anti-rabbit IgG-fluorescein isothiocyanate (Molecular Probes, Eugene, OR) and goat-anti-mouse IgG-Texas Red (1:500 dilution; Molecular Probes). Images were captured on an inverted microscope (Axiovert 200M, Carl Zeiss, inc.) equipped with a spinning disc confocal head (Yogogawa), Argon-Krypton laser system (Prairie Technologies, Inc.), and ORCA-ER CCD camera (Hamamatsu). Images were acquired using the Metamorph software (Molecular Devices) and 3D image reconstruction was performed using the Volocity (Improvision, Inc.) software.
[0039] Example 7. Primary Cultures of Human Kidney Cells [0040] Primary cultures of ADPKD and normal human kidney (NHK) cells were generated with the assistance of the PKD Biomaterials Research Core laboratory at the University of Kansas Medical Center (KUMC). Normal regions of human kidneys, confirmed by histological examination, were collected from nephrectomy specimens removed for the treatment of renal carcinomas. ADPKD kidneys were obtained from hospitals participating in the Polycystic Kidney Research Retrieval Program with the assistance of the PKD
Foundation (Kansas City, MO). The kidneys were packaged within ice and shipped to the laboratory overnight. The protocol for the use of discarded human tissues complies with federal regulations and was approved by the Institutional Review Board at KUMC.
Foundation (Kansas City, MO). The kidneys were packaged within ice and shipped to the laboratory overnight. The protocol for the use of discarded human tissues complies with federal regulations and was approved by the Institutional Review Board at KUMC.
[0041] Primary cell cultures were prepared as described (3). Cells are propagated in DMEM/F12 supplemented with 5% FBS, 5 g/ml insulin, 5 g/ml transferrin and 5 ng/ml sodium selenite (ITS) and 100 IU/ml penicillin G and 0.1 mg/ml streptomycin.
Primary cultures of ADPKD and NHK cells appear epithelial (3-5) and stain with Arachis hypogaea and Dolichos biflorus lectins that bind the collecting ducts and distal tubules (6).
Primary cultures of ADPKD and NHK cells appear epithelial (3-5) and stain with Arachis hypogaea and Dolichos biflorus lectins that bind the collecting ducts and distal tubules (6).
[0042] Example 8. Measurement of TNF-a Concentrations in Human ADPKD Cyst Fluid [0043] Cyst fluids were collected from 10 ADPKD kidneys maintained at 4 C.
The fluid was cleared by centrifugation and aliquots were frozen at -20 C.
The concentrations and total amounts of TNF-a in individual cyst fluids were measured using the DuoSet ELISA
Development kit for human TNF-a/TNFSFIA (R&D Systems, Minneapolis, MN).
The fluid was cleared by centrifugation and aliquots were frozen at -20 C.
The concentrations and total amounts of TNF-a in individual cyst fluids were measured using the DuoSet ELISA
Development kit for human TNF-a/TNFSFIA (R&D Systems, Minneapolis, MN).
[0044] Example 9. Ca2+ Microfluorimetry [0045] The experimental setup for flow was as previously described (7).
Briefly, cells were incubated for 30 min with the Ca2+ sensitive probe Fura2-AM (5 uM) at 37 C. Cells were then washed three times to remove excess Fura2-AM and placed in a perfusion chamber with a thickness of 0.0254 cm and width of 1.0 cm (GlycoTech). The chamber was positioned under a Nikon Diaphot microscope equipped with a CCD camera using IPLab software for Macintosh. Paired Fura images were captured every 5 s at excitation wavelengths of 340 nm and 380 nm. After equilibration in the microscopy media for at least 10 min, the primary cilia of these cells were stimulated at a fluid shear stress of 0.75 dyne crri 2 . The Ca2+ level relative to the baseline value was calculated radiometrically using R,,,;,, and R,,,aX values of 0.3 and 6.0, respectively. In some experiments, cells were incubated with TNF-a (200 ng/ml) for 4 or 16 hours before flow activation. In other experiments, cells were incubated with antibodies against PC2 either extracellular or intracellular domain at a dilution of 1:50 for at least 45 min. Cells were then washed at least three times with phosphate-buffered saline.
Briefly, cells were incubated for 30 min with the Ca2+ sensitive probe Fura2-AM (5 uM) at 37 C. Cells were then washed three times to remove excess Fura2-AM and placed in a perfusion chamber with a thickness of 0.0254 cm and width of 1.0 cm (GlycoTech). The chamber was positioned under a Nikon Diaphot microscope equipped with a CCD camera using IPLab software for Macintosh. Paired Fura images were captured every 5 s at excitation wavelengths of 340 nm and 380 nm. After equilibration in the microscopy media for at least 10 min, the primary cilia of these cells were stimulated at a fluid shear stress of 0.75 dyne crri 2 . The Ca2+ level relative to the baseline value was calculated radiometrically using R,,,;,, and R,,,aX values of 0.3 and 6.0, respectively. In some experiments, cells were incubated with TNF-a (200 ng/ml) for 4 or 16 hours before flow activation. In other experiments, cells were incubated with antibodies against PC2 either extracellular or intracellular domain at a dilution of 1:50 for at least 45 min. Cells were then washed at least three times with phosphate-buffered saline.
[0046] Example 10. Data analysis and statistics [0047] Cytosolic free Ca2+ concentrations were calculated using the formula =
Kd ((R - R,,,;,,) /(R,,,. - R)) (F,,,,,, at 380 nm / F,,,;,, at 380 nm) where Kd denotes apparent dissociation constant of Fura-2 indicator (145 nM), R is the ratio of 510 nm emission intensity when excited at 340 nm to 510 emission intensity when excited at 380 nm, R,,,;,, and Rmax are ratios at zero and saturating (10 mM) Ca2+ concentrations, respectively, and Fmax and F,,;,, are the fluorescence intensity excited at 380 nm at zero and saturating free Ca2+ concentrations, respectively. At the end of the Fura-2 experiments, cells were incubated with calcium-free solution containing 140 mM potassium, 2 mM EGTA and 10 M ionomycin (at pH 8.6 to optimize the ionomycin effect) for about 5 min. This allowed the minimum signal ratio and values of R,,,;,, and F,,,ax at 380 nm to be obtained. Excess Ca2+ was supplied to the cell by adding 10 mM CaC12 to determine the maximum signal ratio. After the 340-nm and 380-nm signals were stable (roughly 3 min), the values of R,,,,,, and F,,,;,, at 380 nm were obtained. All of the fluorescence measurements were then corrected for autofluorescence. All values for statistical significance represent means (s.e.), and each data set was verified to be normally distributed before analysis.
Comparisons were carried out between means using paired Student's t-test. For all comparisons, power analyses were carried out to enable reliable conclusions, and coefficient variances were below 10%. All comparisons with negative results had statistical powers of 0.8, and the statistical significance implies P < 0.05.
Kd ((R - R,,,;,,) /(R,,,. - R)) (F,,,,,, at 380 nm / F,,,;,, at 380 nm) where Kd denotes apparent dissociation constant of Fura-2 indicator (145 nM), R is the ratio of 510 nm emission intensity when excited at 340 nm to 510 emission intensity when excited at 380 nm, R,,,;,, and Rmax are ratios at zero and saturating (10 mM) Ca2+ concentrations, respectively, and Fmax and F,,;,, are the fluorescence intensity excited at 380 nm at zero and saturating free Ca2+ concentrations, respectively. At the end of the Fura-2 experiments, cells were incubated with calcium-free solution containing 140 mM potassium, 2 mM EGTA and 10 M ionomycin (at pH 8.6 to optimize the ionomycin effect) for about 5 min. This allowed the minimum signal ratio and values of R,,,;,, and F,,,ax at 380 nm to be obtained. Excess Ca2+ was supplied to the cell by adding 10 mM CaC12 to determine the maximum signal ratio. After the 340-nm and 380-nm signals were stable (roughly 3 min), the values of R,,,,,, and F,,,;,, at 380 nm were obtained. All of the fluorescence measurements were then corrected for autofluorescence. All values for statistical significance represent means (s.e.), and each data set was verified to be normally distributed before analysis.
Comparisons were carried out between means using paired Student's t-test. For all comparisons, power analyses were carried out to enable reliable conclusions, and coefficient variances were below 10%. All comparisons with negative results had statistical powers of 0.8, and the statistical significance implies P < 0.05.
[0048] Example 11. Modeling [0049] The signaling network for TNF-a represented in figures 7b-d was modeled using an approach that adopts intelligent hybrid systems methods from control systems engineering for modeling reaction kinetics (8). Reactions are embedded in a network structure.
The resulting model is similar to functional Petri nets (9, 10). Computer codes are available upon request. This model computes the relationship between protein concentrations and gene expression levels over a time course. Reactions are executed in a time stepping loop, with time steps of one week. On each time step, the outcome is determined by computing the current rate based on substrate, activator and inhibitor levels. Protein concentrations and gene expression levels are all normalized to a scale ranging from 0 to 1. The balance between production and decay is more important than the precise value of these rates since this balance determines the equilibrium level of each protein. Furthermore, the strength of activation or inhibition of a reaction is defined in qualitative terms (very low, low, medium, etc).
Reaction rates were first assigned by relative values. Then, they were adjusted such that the pathway behavior matched observations. This is essentially manual parameter-fitting to the data.
The resulting model is similar to functional Petri nets (9, 10). Computer codes are available upon request. This model computes the relationship between protein concentrations and gene expression levels over a time course. Reactions are executed in a time stepping loop, with time steps of one week. On each time step, the outcome is determined by computing the current rate based on substrate, activator and inhibitor levels. Protein concentrations and gene expression levels are all normalized to a scale ranging from 0 to 1. The balance between production and decay is more important than the precise value of these rates since this balance determines the equilibrium level of each protein. Furthermore, the strength of activation or inhibition of a reaction is defined in qualitative terms (very low, low, medium, etc).
Reaction rates were first assigned by relative values. Then, they were adjusted such that the pathway behavior matched observations. This is essentially manual parameter-fitting to the data.
[0050] Two production reactions are defined for PC1 and PC2, representing two genes that produce the respective proteins. In the mutant case, one of the PC1 genes is silenced, so the production rate is reduced by 50%. The decay reaction for each of these proteins is constant, at a rate that is 25% of the maximum production rate. To introduce stochastic changes in gene expression, each gene expression "reaction" is set to occur on only 70% of the time steps, chosen randomly. The relative production rates for each PC1 and PC2 reaction are 0.4 and the decay rates are 0.1. If only production and decay reactions occurred for PC1 and PC2, these would have mean equilibrium levels on a 0 to 1 scale of approximately 0.74 in the case of one gene and 0.83 with 2 genes. This follows from basic kinetics and with production rates determined by the rate times the mean expression probability of 0.7.
[0051] The polycystin complex is produced by interaction between PC1 and PC2 proteins, and decays at a constant rate, set again at 1/4 of the maximum production rate. The polycystin complex level fluctuates as a result of random PC1 and PC2 expression. Note that in the wild type the stochastic variation is much smaller than in the mutant.
This is due to offsetting variation in the two separate reactions that represent gene expression and protein production.
Polycystin complex formation is inhibited by FIP2. Thus, as FIP2 levels increase, the reaction for polycystin complex production is inhibited by FIP2 and the decay reaction is activated by FIP2.
This is due to offsetting variation in the two separate reactions that represent gene expression and protein production.
Polycystin complex formation is inhibited by FIP2. Thus, as FIP2 levels increase, the reaction for polycystin complex production is inhibited by FIP2 and the decay reaction is activated by FIP2.
[0052] Cyst growth occurs when polycystin levels drop below an arbitrarily set level of 0.4. In the wild type, polycystin fluctuations are always above this level, so cyst growth never occurs. Below 0.4, cyst growth occurs stochastically, with the chance of cyst growth rising linearly as polycystin levels fall. Cyst growth causes TNF-a production, then TNFR and FIP2 production increase, resulting in suppression of polycystin complex formation.
Renal injury is also defined as a randomly occurring reaction whose only product is TNF-a.
This is modeled as a sudden event that is distinguished from TNF-a increases caused by cyst growth by the sharp rise in concentration that is not preceded by an increase in cyst growth. Rather, cyst growth follows.
Renal injury is defined as having a relatively small chance of occurrence -0.02% in any given week. In the simulations, renal injury events occur in approximately every other lifespan of 80 years and are not always sufficiently large to engage the positive feedback loop and cause PKD
to set in. When injury occurs during a time when polycystin levels are particularly low, such as when cysts have been sporadically forming, the threshold is usually reached and disease occurs.
REFERENCES
Renal injury is also defined as a randomly occurring reaction whose only product is TNF-a.
This is modeled as a sudden event that is distinguished from TNF-a increases caused by cyst growth by the sharp rise in concentration that is not preceded by an increase in cyst growth. Rather, cyst growth follows.
Renal injury is defined as having a relatively small chance of occurrence -0.02% in any given week. In the simulations, renal injury events occur in approximately every other lifespan of 80 years and are not always sufficiently large to engage the positive feedback loop and cause PKD
to set in. When injury occurs during a time when polycystin levels are particularly low, such as when cysts have been sporadically forming, the threshold is usually reached and disease occurs.
REFERENCES
[0053] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
1. Anonymous. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 81, 289-(1995).
2. Hughes, J. et al. The polycystic kidney disease 1(PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 10, 151-60 (1995).
3. Geng, L. et al. Identification and localization of polycystin, the PKD1 gene product. J
Clin Invest 98, 2674-82 (1996).
4. Geng, L. et al. Distribution and developmentally regulated expression of murine polycystin. Am JPhysiol 272, F451-9 (1997).
5. Van Adelsberg, J. S. & Frank, D. The PKD1 gene produces a developmentally regulated protein in mesenchyme and vasculature. Nat Med 1, 359-64 (1995).
6. Ward, C. J. et al. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc Natl Acad Sci U
S A 93, 1524-8 (1996).
7. Peters, D. J. et al. Cellular localization and tissue distribution of polycystin-1. J Pathol 188, 439-46 (1999).
8. Kimberling, W. J. et al. Autosomal dominant polycystic kidney disease:
localization of the second gene to chromosome 4q13-q23. Genomics 18, 467-72 (1993).
9. Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339-42 (1996).
10. Qian, F. et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16, 179-83 (1997).
11. Tsiokas, L., Kim, E., Amould, T., Sukhatme, V. P. & Walz, G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U
S A
94, 6965-70 (1997).
12. Lakkis, M. & Zhou, J. Molecular complexes formed with polycystins. Nephron 93, E3-8 (2003).
13. Delmas, P. et al. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. JBiol Chem 277, 11276-83 (2002).
14. Parnell, S. C. et al. Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277, 19566-72 (2002).
15. Nauli, S. M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33, 129-37 (2003).
16. Cantiello, H. F. A tale of two tails: ciliary mechanotransduction in ADPKD. Trends Mol Med 9, 234-6 (2003).
17. Xu, G. M. et al. Polycystin-1 activates and stabilizes the polycystin-2 channel. J Biol Chem 278, 1457-62 (2003).
18. Hanaoka, K. et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408, 990-4 (2000).
19. Vassilev, P. M. et al. Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem Biophys Res Commun 282, 341-50 (2001).
20. Gonzalez-Perret, S. et al. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel.
Proc Natl Acad Sci U S A 98, 1182-7 (2001).
21. Luo, Y., Vassilev, P. M., Li, X., Kawanabe, Y. & Zhou, J. Native polycystin 2 functions as a plasma membrane Ca2+-permeable cation channel in renal epithelia. Mol Cell Biol 23, 2600-7 (2003).
22. Koulen, P. et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 4, 191-7 (2002).
23. Delmas, P. et al. Gating of the polycystin ion channel signaling complex in neurons and kidney cells. Faseb J 18, 740-2 (2004).
24. Wilson, P. D. Epithelial cell polarity and disease. Am J Physiol 272, F434-42 (1997).
25. Woo, D. Apoptosis and loss of renal tissue in polycystic kidney diseases.
N Engl J Med 333, 18-25 (1995).
26. Nanes, M. S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321, 1-15 (2003).
27. Pfeffer, K. Biological functions of tumor necrosis factor cytokines and their receptors.
Cytokine Growth Factor Rev 14, 185-91 (2003).
28. Bellisarii, F. L., Gallina, S. & De Caterina, R. Tumor necrosis factor-alpha and cardiovascular diseases. Ital Heart J 2, 408-17 (2001).
29. Stenvinkel, P. The role of inflammation in the anaemia of end-stage renal disease.
Nephrol Dial Transplant 16 Supp17, 36-40 (2001).
30. Tartaglia, L. A. & Goeddel, D. V. Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor.
JBiol Chem 267, 4304-7 (1992).
31. Moss, M. L. et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 72, 127-9 (1997).
32. Black, R. A. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34, 1-5 (2002).
33. Rio, C., Buxbaum, J. D., Peschon, J. J. & Corfas, G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275, (2000).
34. Todorov, V., Muller, M., Schweda, F. & Kurtz, A. Tumor necrosis factor-alpha inhibits renin gene expression. Am JPhysiol Regul Integr Comp Physiol 283, R1046-51 (2002).
35. Donnahoo, K. K., Shames, B. D., Harken, A. H. & Meldrum, D. R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162, 196-203 (1999).
36. Donnahoo, K. K. et al. Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia. Immunology 102, (2001).
37. Donnahoo, K. K. et al. Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol 163, 1328-(2000).
38. Gardner, K. D., Jr., Burnside, J. S., Elzinga, L. W. & Locksley, R. M.
Cytokines in fluids from polycystic kidneys. Kidney Int 39, 718-24 (1991).
39. Dell, K. M. et al. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int 60, 1240-8 (2001).
40. Li, Y., Kang, J. & Horwitz, M. S. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol 18, 1601-10 (1998).
41. Wang, S., Luo, Y., Wilson, P. D., Witman, G. B. & Zhou, J. The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. JAm Soc Nephrol 15, 592-602 (2004).
42. Fields, S. & Song, O. A novel genetic system to detect protein-protein interactions.
Nature 340, 245-6 (1989).
43. Hattula, K. & Peranen, J. FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis. Curr Biol 10, 1603-6 (2000).
44. Baldini, G., Hohl, T., Lin, H. Y. & Lodish, H. F. Cloning of a Rab3 isotype predominantly expressed in adipocytes. Proc Natl Acad Sci U S A 89, 5049-52 (1992).
45. Karniguian, A., Zahraoui, A. & Tavitian, A. Identification of small GTP-binding rab proteins in human platelets: thrombin-induced phosphorylation of rab3B, rab6, and rab8 proteins. Proc Natl Acad Sci U S A 90, 7647-51 (1993).
46. Chen, Y. T., Holcomb, C. & Moore, H. P. Expression and localization of two low molecular weight GTP-binding proteins, Rab8 and RablO, by epitope tag. Proc Natl Acad Sci U SA 90, 6508-12 (1993).
47. Torti, M., Ramaschi, G., Sinigaglia, F., Lapetina, E. G. & Balduini, C.
Association of the low molecular weight GTP-binding protein rap2B with the cytoskeleton during platelet aggregation. Proc Natl Acad Sci U S A 90, 7553-7 (1993).
48. Simons, K. & Zerial, M. Rab proteins and the road maps for intracellular transport.
Neuron 11, 789-99 (1993).
49. Rothman, J. E. Mechanisms of intracellular protein transport. Nature 372, 55-63 (1994).
50. Rothman, J. E. & Warren, G. Implications of the SNARE hypothesis for intracellular membrane topology and dynamics. Curr Biol 4, 220-33 (1994).
51. Simonsen, A., Gaullier, J. M., D'Arrigo, A. & Stenmark, H. The Rab5 effector EEA1 interacts directly with syntaxin-6. J Biol Chem 274, 28857-60 (1999).
52. Low, S. H. et al. Differential localization of syntaxin isoforms in polarized Madin-Darby canine kidney cells. Mol Biol Cell 7, 2007-18 (1996).
53. Li, X., Low, S. H., Miura, M. & Weimbs, T. SNARE expression and localization in renal epithelial cells suggest mechanism for variability of trafficking phenotypes.
Am J Physiol Renal Physiol 283, F1111-22 (2002).
1. Anonymous. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 81, 289-(1995).
2. Hughes, J. et al. The polycystic kidney disease 1(PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 10, 151-60 (1995).
3. Geng, L. et al. Identification and localization of polycystin, the PKD1 gene product. J
Clin Invest 98, 2674-82 (1996).
4. Geng, L. et al. Distribution and developmentally regulated expression of murine polycystin. Am JPhysiol 272, F451-9 (1997).
5. Van Adelsberg, J. S. & Frank, D. The PKD1 gene produces a developmentally regulated protein in mesenchyme and vasculature. Nat Med 1, 359-64 (1995).
6. Ward, C. J. et al. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc Natl Acad Sci U
S A 93, 1524-8 (1996).
7. Peters, D. J. et al. Cellular localization and tissue distribution of polycystin-1. J Pathol 188, 439-46 (1999).
8. Kimberling, W. J. et al. Autosomal dominant polycystic kidney disease:
localization of the second gene to chromosome 4q13-q23. Genomics 18, 467-72 (1993).
9. Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339-42 (1996).
10. Qian, F. et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16, 179-83 (1997).
11. Tsiokas, L., Kim, E., Amould, T., Sukhatme, V. P. & Walz, G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U
S A
94, 6965-70 (1997).
12. Lakkis, M. & Zhou, J. Molecular complexes formed with polycystins. Nephron 93, E3-8 (2003).
13. Delmas, P. et al. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. JBiol Chem 277, 11276-83 (2002).
14. Parnell, S. C. et al. Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277, 19566-72 (2002).
15. Nauli, S. M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33, 129-37 (2003).
16. Cantiello, H. F. A tale of two tails: ciliary mechanotransduction in ADPKD. Trends Mol Med 9, 234-6 (2003).
17. Xu, G. M. et al. Polycystin-1 activates and stabilizes the polycystin-2 channel. J Biol Chem 278, 1457-62 (2003).
18. Hanaoka, K. et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408, 990-4 (2000).
19. Vassilev, P. M. et al. Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem Biophys Res Commun 282, 341-50 (2001).
20. Gonzalez-Perret, S. et al. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel.
Proc Natl Acad Sci U S A 98, 1182-7 (2001).
21. Luo, Y., Vassilev, P. M., Li, X., Kawanabe, Y. & Zhou, J. Native polycystin 2 functions as a plasma membrane Ca2+-permeable cation channel in renal epithelia. Mol Cell Biol 23, 2600-7 (2003).
22. Koulen, P. et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 4, 191-7 (2002).
23. Delmas, P. et al. Gating of the polycystin ion channel signaling complex in neurons and kidney cells. Faseb J 18, 740-2 (2004).
24. Wilson, P. D. Epithelial cell polarity and disease. Am J Physiol 272, F434-42 (1997).
25. Woo, D. Apoptosis and loss of renal tissue in polycystic kidney diseases.
N Engl J Med 333, 18-25 (1995).
26. Nanes, M. S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321, 1-15 (2003).
27. Pfeffer, K. Biological functions of tumor necrosis factor cytokines and their receptors.
Cytokine Growth Factor Rev 14, 185-91 (2003).
28. Bellisarii, F. L., Gallina, S. & De Caterina, R. Tumor necrosis factor-alpha and cardiovascular diseases. Ital Heart J 2, 408-17 (2001).
29. Stenvinkel, P. The role of inflammation in the anaemia of end-stage renal disease.
Nephrol Dial Transplant 16 Supp17, 36-40 (2001).
30. Tartaglia, L. A. & Goeddel, D. V. Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor.
JBiol Chem 267, 4304-7 (1992).
31. Moss, M. L. et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 72, 127-9 (1997).
32. Black, R. A. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34, 1-5 (2002).
33. Rio, C., Buxbaum, J. D., Peschon, J. J. & Corfas, G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275, (2000).
34. Todorov, V., Muller, M., Schweda, F. & Kurtz, A. Tumor necrosis factor-alpha inhibits renin gene expression. Am JPhysiol Regul Integr Comp Physiol 283, R1046-51 (2002).
35. Donnahoo, K. K., Shames, B. D., Harken, A. H. & Meldrum, D. R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162, 196-203 (1999).
36. Donnahoo, K. K. et al. Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia. Immunology 102, (2001).
37. Donnahoo, K. K. et al. Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol 163, 1328-(2000).
38. Gardner, K. D., Jr., Burnside, J. S., Elzinga, L. W. & Locksley, R. M.
Cytokines in fluids from polycystic kidneys. Kidney Int 39, 718-24 (1991).
39. Dell, K. M. et al. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int 60, 1240-8 (2001).
40. Li, Y., Kang, J. & Horwitz, M. S. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol 18, 1601-10 (1998).
41. Wang, S., Luo, Y., Wilson, P. D., Witman, G. B. & Zhou, J. The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. JAm Soc Nephrol 15, 592-602 (2004).
42. Fields, S. & Song, O. A novel genetic system to detect protein-protein interactions.
Nature 340, 245-6 (1989).
43. Hattula, K. & Peranen, J. FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis. Curr Biol 10, 1603-6 (2000).
44. Baldini, G., Hohl, T., Lin, H. Y. & Lodish, H. F. Cloning of a Rab3 isotype predominantly expressed in adipocytes. Proc Natl Acad Sci U S A 89, 5049-52 (1992).
45. Karniguian, A., Zahraoui, A. & Tavitian, A. Identification of small GTP-binding rab proteins in human platelets: thrombin-induced phosphorylation of rab3B, rab6, and rab8 proteins. Proc Natl Acad Sci U S A 90, 7647-51 (1993).
46. Chen, Y. T., Holcomb, C. & Moore, H. P. Expression and localization of two low molecular weight GTP-binding proteins, Rab8 and RablO, by epitope tag. Proc Natl Acad Sci U SA 90, 6508-12 (1993).
47. Torti, M., Ramaschi, G., Sinigaglia, F., Lapetina, E. G. & Balduini, C.
Association of the low molecular weight GTP-binding protein rap2B with the cytoskeleton during platelet aggregation. Proc Natl Acad Sci U S A 90, 7553-7 (1993).
48. Simons, K. & Zerial, M. Rab proteins and the road maps for intracellular transport.
Neuron 11, 789-99 (1993).
49. Rothman, J. E. Mechanisms of intracellular protein transport. Nature 372, 55-63 (1994).
50. Rothman, J. E. & Warren, G. Implications of the SNARE hypothesis for intracellular membrane topology and dynamics. Curr Biol 4, 220-33 (1994).
51. Simonsen, A., Gaullier, J. M., D'Arrigo, A. & Stenmark, H. The Rab5 effector EEA1 interacts directly with syntaxin-6. J Biol Chem 274, 28857-60 (1999).
52. Low, S. H. et al. Differential localization of syntaxin isoforms in polarized Madin-Darby canine kidney cells. Mol Biol Cell 7, 2007-18 (1996).
53. Li, X., Low, S. H., Miura, M. & Weimbs, T. SNARE expression and localization in renal epithelial cells suggest mechanism for variability of trafficking phenotypes.
Am J Physiol Renal Physiol 283, F1111-22 (2002).
54. Ramesh, G. & Reeves, W. B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110, 835-42 (2002).
55. Koksoy, C., Kuzu, M. A., Kuzu, I., Ergun, H. & Gurhan, I. Role of tumour necrosis factor in lung injury caused by intestinal ischaemia-reperfusion. Br J Surg 88, 464-8 (2001).
56. Kupatt, C. et al. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. Circ Res 84, 392-400 (1999).
57. Lan, H. Y. et al. TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 3, 136-44 (1997).
58. Moutabarrik, A., Nakanishi, I., Matsumoto, M., Zaid, D. & Seya, T. Human glomerular epithelial cells synthesize and secrete the third component of complement.
Nephron 70, 55-61 (1995).
Nephron 70, 55-61 (1995).
59. Macica, C. M., Escalante, B. A., Conners, M. S. & Ferreri, N. R. TNF
production by the medullary thick ascending limb of Henle's loop. Kidney Int 46, 113-21 (1994).
production by the medullary thick ascending limb of Henle's loop. Kidney Int 46, 113-21 (1994).
60. Olkkonen, V. M. & Stenmark, H. Role of Rab GTPases in membrane traffic.
Int Rev Cytol 176, 1-85 (1997).
Int Rev Cytol 176, 1-85 (1997).
61. Clague, M. J. Membrane transport: Take your fusion partners. Curr Biol 9, (1999).
62. Grote, E. & Novick, P. J. Promiscuity in Rab-SNARE interactions. Mol Biol Cell 10, 4149-61 (1999).
63. Ungar, D. & Hughson, F. M. SNARE protein structure and function. Annu Rev Cell Dev Biol 19, 493-517 (2003).
64. Pfeffer, S. R. Transport-vesicle targeting: tethers before SNAREs. Nat Cell Biol 1, E17-22 (1999).
65. Weber, T. et al. SNAREpins: minimal machinery for membrane fusion. Cell 92, 759-72 (1998).
66. Ungermann, C., Sato, K. & Wickner, W. Defining the functions of trans-SNARE pairs.
Nature 396, 543-8 (1998).
Nature 396, 543-8 (1998).
67. Yang, B. et al. SNARE interactions are not selective. Implications for membrane fusion specificity. JBiol Chem 274, 5649-53 (1999).
68. Novick, P. & Zerial, M. The diversity of Rab proteins in vesicle transport. Curr Opin Cell Biol 9, 496-504 (1997).
69. Qian, F., Watnick, T. J., Onuchic, L. F. & Germino, G. G. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.
Cell 87, 979-87 (1996).
Cell 87, 979-87 (1996).
70. Brasier, A. R., Li, J. & Wimbish, K. A. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 27, 1009-17 (1996).
71. Miller-Hjelle, M. A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg Infect Dis 3, 113-27 (1997).
72. Foggensteiner, L. et al. Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene. JAm Soc Nephrol 11, 814-27 (2000).
73. Pazour, G. J., San Agustin, J. T., Follit, J. A., Rosenbaum, J. L. &
Witman, G. B.
Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 12, R378-80 (2002).
Witman, G. B.
Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 12, R378-80 (2002).
Claims (31)
1. A method of inhibiting cyst formation comprising inhibiting TNF-.alpha.
signalling such that polycystin function is maintained in a cell.
signalling such that polycystin function is maintained in a cell.
2. The method of claim 1, wherein the TNF-.alpha. signalling is selected from the group consisting of TNF-.alpha., Rab8, TNF-.alpha. receptor, fibrocystin, FIP2 and TNF-.alpha. receptor-associated proteins.
3. The method of claim 2, wherein the TNF-.alpha. signalling comprises fibrocystin.
4. The method of claim 2, wherein the TNF-.alpha. signalling comprises FIP2.
5. The method of claim 2, wherein the TNF-.alpha. signalling comprises TNF-.alpha..
6. The method of claim 1, wherein the cell comprises a pancreatic cell, a kidney cell or a liver cell.
7. The method of claim 6, wherein the cell comprises a pancreatic cell.
8. The method of claim 6, wherein the cell comprises a kidney cell.
9. The method of claim 6, wherein the cell comprises a liver cell.
10. The method of claim 1, wherein the TNF-.alpha. signalling is inhibited in vivo.
11. The method of claim 1, wherein the TNF-.alpha. signalling is inhibited in vitro.
12. The method of claim 1, wherein polycystin function is maintained such that cystogenesis is inhibited.
13. The method of claim 1, wherein polycystin function is maintained such that PC2 remains localized to the plasma membrane of the cell.
14. A method of inhibiting the disruption of calcium influx into a cell comprising inhibiting TNF-.alpha. signalling such that polycystin function is maintained in a cell.
15. A method of inhibiting the disruption of calcium influx into a cell comprising inhibiting FIP2 interaction with PC2 such that PC2 remains localized to the plasma membrane of a cell.
16. A method of treating a haploinsufficiency-associated disease comprising inhibiting TNF-.alpha. signalling such that polycystin function is maintained in a cell.
17. The method of claim 16, wherein the haploinsufficiency-associated disease comprises autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, neurofibromatosis, neuroblastoma or MODY diabetes.
18. The method of claim 16, wherein TNF-.alpha. signalling is inhibited by an antibody to TNF-.alpha., Rab8, TNF-.alpha. receptor, fibrocystin, FIP2 or a TNF-.alpha. receptor-associated protein.
19. The method of claim 16, wherein TNF-.alpha. signalling is inhibited by etanercept, infliximab, D2E7, CDP 571, CDP 870, onercept, OR1384, tenidap, rapamycin, or leflunomide.
20. A composition comprising an antibody, or antigen-binding fragment thereof, that binds substantially to TNF-.alpha., Rab8, TNF-.alpha. receptor, fibrocystin, FIP2 or a TNF-.alpha. receptor-associated protein such that polycystin function is maintained in a cell and cystogenesis is inhibited.
21. The composition of claim 19, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof.
22. The composition of claim 19, wherein the antibody is an IgG antibody or an IgM
antibody.
antibody.
23. The composition of claim 19, wherein the antigen-binding fragment is an scFv, Fv, Fab', Fab, diabody, linear antibody or F(ab')2 antigen-binding fragment of an antibody.
24. The composition of claim 19, wherein the antibody is a dimer, trimer or multimer of the antibody or antigen-binding fragments thereof.
25. The composition of claim 19, wherein the antibody is a human, humanized or part-human antibody or antigen-binding fragment thereof.
26. The composition of claim 19, wherein the antibody is a chimeric antibody.
27. The composition of claim 19, wherein the antibody is a recombinant antibody.
28. The composition of claim 19, wherein the antibody is operatively attached to at least a first therapeutic or diagnostic agent.
29. The composition of claim 27, wherein the antibody is operatively attached to at least a first and a second therapeutic agent.
30. A pharmaceutical composition comprising a biologically effective amount of at least a first immunoconjugate comprising an antibody, or antigen-binding fragment thereof, that binds substantially to TNF-.alpha., Rab8, TNF-.alpha. receptor, fibrocystin, FIP2 or a TNF-.alpha.
receptor-associated protein such that cystogenesis is inhibited and polycystin function is maintained in a cell.
receptor-associated protein such that cystogenesis is inhibited and polycystin function is maintained in a cell.
31. A compound comprising an antibody or an antigen-binding portion thereof operatively attached to a therapeutic agent, wherein the antibody, or antigen-binding portion thereof, binds substantially to TNF-.alpha., Rab8, TNF-.alpha. receptor, fibrocystin, FIP2 or a TNF-.alpha.
receptor-associated protein, such that the therapeutic agent inhibits TNF-.alpha. signalling and polycystin function is maintained in a cell.
receptor-associated protein, such that the therapeutic agent inhibits TNF-.alpha. signalling and polycystin function is maintained in a cell.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74418206P | 2006-04-03 | 2006-04-03 | |
US60/744,182 | 2006-04-03 | ||
US82587306P | 2006-09-15 | 2006-09-15 | |
US60/825,873 | 2006-09-15 | ||
PCT/US2007/065869 WO2007118084A2 (en) | 2006-04-03 | 2007-04-03 | Compositions and methods for treating polycystic kidney disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2648407A1 true CA2648407A1 (en) | 2007-10-18 |
Family
ID=38581793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002648407A Abandoned CA2648407A1 (en) | 2006-04-03 | 2007-04-03 | Compositions and methods for treating polycystic kidney disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2035038A4 (en) |
JP (1) | JP2009532495A (en) |
CA (1) | CA2648407A1 (en) |
WO (1) | WO2007118084A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006097A2 (en) * | 2009-07-10 | 2011-01-13 | The Brigham And Women's Hospital, Inc. | Methods For Treating Toxicity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750495A (en) * | 1996-03-26 | 1998-05-12 | The Regents Of The University Of California | Treatment of cystic disease with TNF-α |
WO2000037085A1 (en) * | 1998-12-18 | 2000-06-29 | Scios Inc. | Treatment of diseases involving cyst formation |
US6638726B1 (en) * | 2000-01-06 | 2003-10-28 | Mount Sinai School Of Medicine Of New York University | Screening methods for compounds useful in the treatment of polycystic kidney disease |
US7488754B2 (en) * | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
CN1832928B (en) * | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 5-membered heterocycle-based p38 kinase inhibitors |
TW201705980A (en) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | Multiple-variable dose regimen for treating TNF[alpha]-related disorders |
-
2007
- 2007-04-03 JP JP2009504420A patent/JP2009532495A/en active Pending
- 2007-04-03 WO PCT/US2007/065869 patent/WO2007118084A2/en active Application Filing
- 2007-04-03 CA CA002648407A patent/CA2648407A1/en not_active Abandoned
- 2007-04-03 EP EP07760034A patent/EP2035038A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2009532495A (en) | 2009-09-10 |
EP2035038A4 (en) | 2011-04-06 |
WO2007118084A2 (en) | 2007-10-18 |
EP2035038A2 (en) | 2009-03-18 |
WO2007118084A3 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | HAb18G/CD147 promotes cell motility by regulating annexin II‐activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells | |
Cantiello | Regulation of calcium signaling by polycystin-2 | |
Terenzi et al. | Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity | |
Soloviev et al. | Molecular characterisation of two structurally distinct groups of human homers, generated by extensive alternative splicing | |
ES2252494T3 (en) | NATURAL BINDING OF GPRC CHEMR23 AND USES OF THE SAME. | |
KR20090089462A (en) | Compositions and methods for treating pathologic angiogenesis and vascular permeability | |
KR20110090842A (en) | Pharmaceutical composition for inhibiting abnormal cell proliferation | |
JP2012512170A (en) | Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis | |
Moik et al. | Mutations in the paxillin-binding site of integrin-linked kinase (ILK) destabilize the pseudokinase domain and cause embryonic lethality in mice | |
WO1995006415A1 (en) | Senescent cell-derived inhibitors of dna synthesis | |
Salim et al. | The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells | |
Schaffner-Reckinger et al. | The actin-bundling protein L-plastin—A double-edged sword: Beneficial for the immune response, maleficent in cancer | |
EP3131922B1 (en) | Polypeptides and uses thereof for reducing cd95-mediated cell motility | |
CA2648407A1 (en) | Compositions and methods for treating polycystic kidney disease | |
Sporkova et al. | Lin11-Isl1-Mec3 domain proteins as mechanotransducers in endothelial and vascular smooth muscle cells | |
Kirilenko et al. | The efficiency of Xenopus primordial germ cell migration depends on the germplasm mRNA encoding the PDZ domain protein Grip2 | |
Sun et al. | A member of the Y-box protein family interacts with an upstream element in the α1 (I) collagen gene | |
JP2007505825A (en) | Use of eukaryotic genes that influence cell cycle control or cell cycle progression in the diagnosis and treatment of proliferative diseases | |
Qian | The role of G-protein coupled receptor proteolytic site (GPS) cleavage in polycystin-1 biogenesis, trafficking and function | |
US9107936B2 (en) | Antagonists of GRASP55 for use as a medicament | |
JP7325075B2 (en) | For screening at least one agent selected from the group consisting of agents for increasing or decreasing the number of frizzled 3-expressing cells, agents for preventing or treating diabetes, agents for preventing or treating insulinoma, and agents for promoting or suppressing insulin secretion Screening Agent, Screening Kit, and Screening Method | |
Guerrera | PDZD11: a novel PLEKHA7 interactor at adherens junctions | |
Hegazy | The Role of Desmoglein-1 in Epidermal Stratification Via Retromer-Mediated Recycling and Actin Regulation | |
Yan | Functional characterization of the role of Bruno protein in translational regulation and germ line development in Drosophila melanogaster | |
Leitner | The role of the transcriptional coactivator MAL and its target genes in cell motility and EMT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20130403 |